These findings suggest that, in bladder cancer cells, ARID1A deficiency induces a biologic dependency on PI3K/AKT signaling that can be pharmacologically targeted through EZH2 inhibition and upregulation of PIK3IP1. The gene discussed is AKT1; the disease is urinary bladder carcinoma.